Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct-Dec;12(4):381-390.
doi: 10.4103/jpbs.JPBS_338_19. Epub 2020 Oct 8.

Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology

Akshyaya Pradhan  1 , Shaweta Vohra  1 , Rishi Sethi  1
Affiliations
Review

Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology

Akshyaya Pradhan et al. J Pharm Bioallied Sci. 2020 Oct-Dec.

Abstract

Conventionally, rennin-angiotensin-aldosterone system (RAAS) inhibition has focused on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and angiotensin receptor-neprilysin inhibitors (ARNI) are the latest addition to this armamentarium. However, mineralocorticoid receptor antagonists (MRAs) also constitute an integral part of this anti-RAAS brigade, which are perceived more often as diuretics and are often under prescribed in heart failure (HF) despite being universally advocated by all major guidelines. Apart from HF, they have also shown promise in the management of hypertension, post-myocardial infarction, and hyperaldosteronism. Eplerenone, Food and Drug Administration (FDA) approved in 2002, is an acceptable alternative to spironolactone due to its sparing androgenic effects. In two big pivotal trials in heart failure (EMPHASIS -HF) and post-myocardial infarction (EPHESUS), the drug has firmly shown a reduction in adverse cardiovascular events. It has an established place in the management of resistant hypertension too. In this article, we will discuss the role of RAAS and its pathophysiology, pitfalls of spironolactone, which led to success of its congener, eplerenone, major studies conducted on eplerenone, current role of eplerenone, and comparison of the two MRAs.

Keywords: Eplerenone; gynecomastia; heart failure; hyperkalemia; mineralocorticoid receptor antagonist; resistant hypertension.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Heart failure syndrome resulting from angiotensin II: the key product of RAAS cascade. HF = heart failure, AT = angiotensin, SNS = sympathetic nervous system, ANP = atrial natriuretic peptide, BNP = brain natriuretic peptide
Figure 2
Figure 2
Pitfalls of spironolactone. HbA1C = glycosylated hemoglobin
Figure 3
Figure 3
Advantages and disadvantages of eplerenone. CYP3A4 = cytochrome P450 3A4 enzyme
Figure 4
Figure 4
Potential contraindications and cautions for eplerenone use in clinical practice. NSAID = nonsteroidal anti-inflammatory drugs
Figure 5
Figure 5
Outline of management of hyperkalemia in patients on MRA. MRA = mineralocorticoid receptor antagonist
See this image and copyright information in PMC

References

    1. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459–69. - PMC - PubMed
    1. Richards AM, Nicholls MG. Aldosterone antagonism in heart failure. Lancet. 1999;354:789–90. - PubMed
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. Authors/Task Force Members; Document Reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. - PubMed
    1. Chaggar PS, Malkin CJ, Shaw SM, Williams SG, Channer KS. Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovasc Ther. 2009;27:187–93. - PubMed
    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. - PubMed